Bio-Gene Technology Ltd (BGT) - Total Liabilities

Latest as of December 2025: AU$307.71K AUD ≈ $217.72K USD

Based on the latest financial reports, Bio-Gene Technology Ltd (BGT) has total liabilities worth AU$307.71K AUD (≈ $217.72K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore BGT operating cash flow to assess how effectively this company generates cash.

Bio-Gene Technology Ltd - Total Liabilities Trend (2014–2025)

This chart illustrates how Bio-Gene Technology Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Bio-Gene Technology Ltd (BGT) asset resilience to evaluate the company's liquid asset resilience ratio.

Bio-Gene Technology Ltd Competitors by Total Liabilities

The table below lists competitors of Bio-Gene Technology Ltd ranked by their total liabilities.

Company Country Total Liabilities
Avalon Holdings Corporation
NYSE MKT:AWX
USA $53.32 Million
Turnstone Biologics Corp. Common Stock
NASDAQ:TSBX
USA $6.34 Million
Conduit Holdings Ltd
LSE:CRE
UK GBX1.08 Billion
BIG Industries Bhd
KLSE:7005
Malaysia RM17.55 Million
Eddy Smart Home Solutions Ltd
V:EDY
Canada CA$17.07 Million
Star Minerals Ltd
AU:SMS
Australia AU$291.54K
Conquest Resources Ltd
V:CQR
Canada CA$81.65K
Tempo Inti Media Tbk
JK:TMPO
Indonesia Rp206.41 Billion

Liability Composition Analysis (2014–2025)

This chart breaks down Bio-Gene Technology Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Bio-Gene Technology Ltd market cap and net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 4.31 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.26 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.21 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Bio-Gene Technology Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Bio-Gene Technology Ltd (2014–2025)

The table below shows the annual total liabilities of Bio-Gene Technology Ltd from 2014 to 2025.

Year Total Liabilities Change
2025-06-30 AU$522.98K
≈ $370.04K
+41.94%
2024-06-30 AU$368.45K
≈ $260.70K
-39.98%
2023-06-30 AU$613.88K
≈ $434.36K
-40.67%
2022-06-30 AU$1.03 Million
≈ $732.10K
+37.12%
2021-06-30 AU$754.57K
≈ $533.91K
+33.01%
2020-06-30 AU$567.29K
≈ $401.39K
-7.55%
2019-06-30 AU$613.61K
≈ $434.17K
-19.22%
2018-06-30 AU$759.59K
≈ $537.46K
+103.13%
2017-06-30 AU$373.94K
≈ $264.58K
-2.37%
2016-06-30 AU$383.00K
≈ $271.00K
+40004.71%
2014-06-30 AU$955.00
≈ $675.72
--

About Bio-Gene Technology Ltd

AU:BGT Australia Biotechnology
Market Cap
$8.20 Million
AU$11.59 Million AUD
Market Cap Rank
#27329 Global
#1398 in Australia
Share Price
AU$0.04
Change (1 day)
+2.70%
52-Week Range
AU$0.02 - AU$0.04
All Time High
AU$0.34
About

Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of naturally derived insecticide products in Australia and internationally. Its products include Flavocide, a synthetically produced nature-identical compound; and Qcide, a natural plant-derived oil with high levels of tasmanone. The company has a research collaboration agreement with Jame… Read more